CalciMedica files audited FY2022 financials post-reverse merger; net loss $14.5M

CalciMedica, Inc.

Net loss of $14.5M in 2022, accumulated deficit $118.4M as of Dec 31, 2022.
Cash and cash equivalents $1.3M at year-end 2022; merger and private placement raised ~$34.2M in March 2023.
Reverse merger closed March 20, 2023; Graybug Vision renamed CalciMedica, surviving as public entity.
Former CalciMedica stockholders own ~72% of combined company on fully diluted basis.
Going concern opinion included; management expects new funds to support operations beyond 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.